Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Omni Pharma Execs On China Following A Different Pharma Model Than India: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a JV between two former principal R&D leaders from Ivax/Tevaand Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and COO Shaochuan Zeng, the two former leaders from Ivax/Teva, spoke with PharmAsia News about their operation and Chinese pharmas going international.

You may also be interested in...



With Two Deals In Place, Amerigen Looks To Leverage China For Branded Generics

U.S. startup looks to tap into China’s generic market – both in China and back home in the states.

Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)

Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.

Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)

Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.

Latest News
See All
UsernamePublicRestriction

Register

SC069514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel